Sunday, July 5, 2026
🇺🇸 FDA

QA/QC Tools · Stability · ICH Q1A

Stability Schedule Generator

Generate ICH Q1A-compliant stability study schedules with exact testing dates and acceptable windows. Pharma Stability sells inspection-ready protocol templates; this free tool calculates live pull dates from your start date.

Quick Answer

ICH Q1A(R2) defines stability testing timepoints and acceptable pull windows for pharmaceutical shelf-life studies. Enter a study start date, storage condition (long-term Zone I/II or III/IV, intermediate, accelerated, refrigerated, frozen), duration, and product type to generate exact target dates with ±3/±7/±14-day windows per ICH. Long-term 24-month shelf life requires T=0, 3, 6, 9, 12, 18, and 24 months; accelerated requires T=0, 3, and 6 months. Samples pulled outside the window require documented deviation investigation.

Study parameters

Enter the study start date, storage condition, duration, and product type to generate ICH Q1A timepoints with acceptable windows.

Schedule inputs
Timepoint Target Date Earliest (Window) Latest (Window) Status Notes

ICH Q1A Storage Conditions Reference

Condition Temperature Humidity Typical Duration
Long-term (Zone I/II)25°C ± 2°C60% RH ± 5%12 months minimum
Intermediate30°C ± 2°C65% RH ± 5%6 months
Accelerated40°C ± 2°C75% RH ± 5%6 months
Long-term (Zone III/IV)30°C ± 2°C65% RH ± 5%12 months minimum
Refrigerated5°C ± 3°C—Duration of shelf life
Frozen-20°C ± 5°C—Duration of shelf life

ICH Q1A Acceptable Timepoint Windows

Timepoint Acceptable Window Notes
T=0 (Initial)Day of manufactureBaseline testing — same day or within defined limit
T=1 month± 3 days
T=3 months± 7 days
T=6 months± 7 daysAccelerated study endpoint (minimum)
T=9 months± 14 daysSome guidelines allow ± 7 days
T=12 months± 14 daysAnnual shelf-life data point
T=18 months± 14 days
T=24 months± 14 days2-year shelf-life endpoint
T=36 months± 14 days3-year shelf-life endpoint

How to Use This Generator

1
Enter the study start date—when samples entered the stability chamber.
2
Select storage condition matching your protocol and target market climatic zone.
3
Choose duration (6–36 months), product type, and study type (new, ongoing, post-approval).
4
Click Generate Stability Schedule to view timepoints with target dates and ICH windows.
5
Copy as CSV for LIMS or print for laboratory pull logs. Flag overdue timepoints for deviation review.

Worked Example

24-month drug product — long-term Zone I/II

Start date: 1 January 2026 · Condition: 25°C/60% RH · Duration: 24 months
Generated timepoints: T=0 (1 Jan 2026), T=3 (1 Apr ±7d), T=6 (1 Jul ±7d), T=9 (1 Oct ±14d), T=12 (1 Jan 2027 ±14d), T=18 (1 Jul 2027 ±14d), T=24 (1 Jan 2028 ±14d)
Accelerated companion study: Same start date at 40°C/75% RH requires only T=0, 3, and 6 months.

Pharma / GMP Context for QA Professionals

Stability scheduling underpins Module 3.2.P.8 shelf-life claims and annual stability commitments. QC stability coordinators must align chamber pulls with protocol-approved windows—missed pulls are among the most common stability-related audit observations. This generator automates date arithmetic that teams otherwise maintain in Excel, reducing transcription errors before LIMS entry.

Climatic zone selection affects global filing strategy: products marketed in hot-humid regions (Zone IV) may require 30°C/65% RH long-term data instead of 25°C/60% RH. When accelerated data show significant change, intermediate 30°C/65% RH studies bridge to long-term claims. Refrigerated biologics follow 5°C ± 3°C with shelf-life-duration testing.

Link stability operations to quality event management: chamber temperature excursions use the Deviation Report Template; failing results trigger the OOS Investigation Template; systemic chamber issues escalate to the CAPA Template.

Evidence and Sources

Frequently Asked Questions

ICH Q1A(R2) is the stability testing guideline for new drug substances and products developed under the International Council for Harmonisation. It defines storage conditions, testing timepoints, and minimum data requirements for stability sections of regulatory submissions (NDA, MAA, CTD Module 3.2.P.8).
Per ICH Q1A(R2): the 1-month timepoint has a window of ±3 days; the 3-month and 6-month timepoints have ±7 days; the 9-month timepoint and all subsequent timepoints (12, 18, 24, 36 months) have ±14 days. Pulling samples outside these windows constitutes a deviation that must be documented.
ICH Q1A defines climatic zones based on mean kinetic temperature and humidity. Zone I (temperate) and Zone II (Mediterranean/subtropical) use 25°C/60% RH as the long-term condition. Zone III (hot/dry) and Zone IV (hot/humid) use 30°C/65% RH (Zone IVA) or 30°C/75% RH (Zone IVB) as the long-term condition. The intended market determines which zone applies.
For a 24-month proposed shelf life, the minimum required timepoints are: T=0, 3, 6, 9, 12, 18, and 24 months for long-term storage conditions; and T=0, 3, and 6 months for accelerated (40°C/75% RH) storage conditions. Intermediate conditions (30°C/65% RH for 6 months) are required when accelerated data shows significant change.
Document the deviation immediately in the stability system. An OOS investigation may be required if the time deviation is significant or if results are unexpected. Results pulled outside the ICH window may still be usable in the regulatory submission with appropriate justification, but the deviation must be recorded in the stability study report.
Accelerated storage is 40°C/75% RH for 6 months minimum and helps predict long-term degradation kinetics. Intermediate storage (30°C/65% RH for 6 months) is triggered when significant change occurs at accelerated conditions while long-term data remain compliant. Intermediate data bridge accelerated failures to long-term shelf-life claims without immediately reducing expiry dating.
ICH Q1A(R2) requires stability data from three primary batches of drug substance or drug product manufactured at the same scale and process intended for commercial production. Each batch should use the same container-closure system as the marketed product. Bracketing and matrixing designs may reduce testing under defined conditions per ICH Q1D.
Refrigerated products use 5°C ± 3°C long-term storage for the duration of the proposed shelf life. Humidity is not specified because impermeable or semi-permeable container effects dominate. Accelerated conditions for refrigerated products may use 25°C/60% RH if justified; this generator includes refrigerated and frozen condition schedules.
Yes. Post-approval stability commitments follow the same ICH Q1A timepoint logic unless a variation-specific protocol defines otherwise. Annual batches placed on stability typically use long-term conditions with timepoints through the approved shelf life. Select "Post-Approval" study type and match duration to your registration commitment.
Significant change at accelerated conditions includes failure to meet release specifications, degradation exceeding acceptance criteria, or failure of critical quality attributes compared to initial (T=0) results. When significant change occurs, intermediate testing and possibly reduced shelf-life claims are required. The stability report must document the statistical assessment.
Missed stability pulls, chamber excursions, and OOS stability results require deviation investigation per GMP. Use the Deviation Report Template for protocol non-conformance and the OOS Investigation Template when analytical results fail specification. Stability schedule adherence is a common FDA inspection focus area.
Pair stability scheduling with the GMP Checklist Generator (QC laboratory items), CAPA Template for chamber failures, Deviation Template for missed pulls, and OOS Investigation for failing stability results. Process Capability Cpk supports method validation trending during stability method transfer.

Related Tools

☰RPN Calculator 🏭Cleanroom Classification 📋CAPA Template ✅GMP Checklist

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.